Table I.
Patient data
| Patient No. | Age (y) | Sex | Zap70 | Doubling Time | Previous Chemotherapy | RAI Stage | Modified RAI Risk (iwCLL) | In Our Study |
|---|---|---|---|---|---|---|---|---|
| 1 | 79 | M | Positive | 3 mo | No | II | Intermediate | Early |
| 2 | 50 | M | ND | 2 mo | FC/R | IV | High | Advanced |
| 3 | 72 | M | Negative | NA | COP/R | IV | High | Advanced |
| 4 | 62 | F | Positive | Not reached | No | 0 | Low | Early |
| 5 | 52 | M | Positive | 6 mo | No | 0 | Low | Early |
| 6 | 84 | F | Positive | 2 y | None | 0 | Low | Early |
| 7 | 76 | F | Positive | 3 mo | FC/R | IV | High | Advanced |
| 8 | 75 | F | ND | 12 mo | No | 0 | Low | Early |
| 9 | 59 | M | Negative | Not reached | No | I | Intermediate | Early |
| 10 | 82 | F | Positive | 7 mo | No | I | Intermediate | Early |
| 11 | 76 | F | Positive | 2 mo | L/P, FC/R | IV | High | Advanced |
| 12 | 75 | M | Negative | Not reached | No | 0 | Low | Early |
| 13 | 58 | F | Positive | NA | COP | IV | High | Advanced |
| 14 | 84 | M | Positive | 1.5 y | No | 0 | Low | Early |
| 15 | 59 | F | Positive | 3 mo | L/P | II | Intermediate | Early |
| 16 | 72 | F | Negative | 3 mo | COP | III | High | Advanced |
| 17 | 67 | F | Positive | Not reached | No | 0 | Low | Early |
| 18 | 74 | M | ND | 10 mo | No | II | Intermediate | Early |
| 19 | 60 | M | Positive | Not reached | No | 0 | Low | Early |
| 20 | 80 | F | Negative | 12 mo | No | 0/I | Intermediate | Early |
| 21 | 70 | M | Positive | NA | L/P | IV | High | Advanced |
| 22 | 86 | F | Positive | Not reached | No | II | Intermediate | Early |
| 23 | 72 | M | Negative | NA | FC | III | High | Advanced |
| 24 | 63 | M | Positive | NA | CHOP-like | IV | High | Advanced |
| 25 | 78 | M | Positive | 1 mo | FCR, L/P | IV | High | Advanced |
| 26 | 88 | M | ND | Newly diagnosed | No | IV | High | Advanced |
| 27 | 70 | M | Negative | Not reached | No | I | Intermediate | Early |
| 28 | 82 | M | Positive | Not reached | No | I | Intermediate | Early |
| 29 | 74 | F | Negative | Not reached | No | 0 | Low | Early |
| 30 | 81 | F | Positive | 2 mo | L/P | III | High | Advanced |
| 31 | 80 | M | positive | Not reached | No | I | Intermediate | Early |
| 32 | 80 | F | Positive | >2 y | L/P | IV | High | Advanced |
| 33 | 76 | M | Positive | NA | L/P | IV | High | Advanced |
| 34 | 65 | M | ND | Not reached | No | 0 | Low | Early |
| 35 | 49 | M | Positive | Not reached | No | 0 | Low | Early |
| 36 | 50 | F | ND | 8 mo | L/P | III | High | Advanced |
| 37 | 60 | M | Negative | 24 mo | No | II | Intermediate | Early |
| 38 | 70 | M | Negative | Not reached | No | I | Intermediate | Early |
| 39 | 56 | F | ND | 6 mo | L/P | I | Intermediate | Early |
| 40 | 75 | F | Positive | 12 mo | No | 0 | Low | Early |
| 41 | 72 | F | ND | Not reached | No | 0 | Low | Early |
| 42 | M | Positive | 3 mo | FCR | IV | High | Advanced | |
| 43 | F | Negative | Several y | No | I | Intermediate | Early | |
| 44 | F | Negative | Not reached | No | II | Intermediate | Early | |
| 45 | 77 | M | Positive | 3 mo | COP | III | High | Advanced |
| 46 | 80 | M | Positive | 5 mo | COP, FCR | IV | High | Advanced |
| 47 | 54 | M | Positive | 2 mo | FCR | II | Intermediate | Early |
| 48 | 78 | F | ND | Not reached | No | 0 | Low | Early |
| 49 | 34 | M | Negative | 12 mo | No | I | Intermediate | Early |
| 50 | 50 | F | Negative | Not reached | No | I | Intermediate | Early |
| 51 | 73 | F | Positive | 6 mo | L/P, CHOP | IV | High | Advanced |
| 52 | 77 | M | ND | Not reached | No | 0 | Low | Early |
| 53 | 55 | F | Negative | 6 mo | Newly diagnosed | IV | High | Advanced |
| 54 | 65 | M | Negative | 1 y | No | I | Intermediate | Early |
| 55 | 70 | F | Negative | Not reached | No | 0 | Low | Early |
| 56 | 76 | F | Negative | Not reached | No | 0 | Low | Early |
| 57 | 76 | F | Negative | Not reached | No | 0–I | Intermediate | Early |
| 58 | 72 | M | Positive | 2 mo | CHOP-like | IV | High | Advanced |
| 59 | 65 | M | Positive | 3 y | No | 0 | Low | Early |
| 60 | 75 | F | Positive | 12 mo | No | 0 | Low | Early |
| 61 | 70 | F | ND | Not reached | No | I | Intermediate | Early |
| 62 | 73 | M | Negative | Not reached | No | I | Intermediate | Early |
| 63 | 67 | M | Positive | 6 mo | No | I | Intermediate | Early |
| 64 | 82 | F | Negative | 3 mo | L/P | IV | High | Advanced |
| 65 | 76 | M | ND | 3 mo | COP | IV | High | Advanced |
| 66 | 60 | M | Negative | 8 mo | No | II | Intermediate | Early |
| 67 | 83 | F | Positive | 6 mo | L/P | I | Intermediate | Early |
| 68 | 80 | F | Negative | 6 mo | L/P | IV | High | Advanced |
| 69 | 65 | M | ND | NA | FCR, APSCT | IV | High | Advanced |
| 70 | 60 | F | Positive | 1 y | L/P | I | Intermediate | Early |
Patient's samples were drawn at least 6 wk after the last dose of chemotherapy.
APSCT, autologous peripheral stem cell transplantation; COP/CHOP, cyclophosphamide, oncovine, and prednisone, with or without an anthracycline; F, female; FC/R, fludarabine and cyclophosphamide with or without rituximab; L/P, leukeran/prednisone; M, male; NA, not applicable.